Last reviewed · How we verify

Cotrimoxazole dispersible tablet

University of Oxford · Phase 3 active Small molecule

Cotrimoxazole dispersible tablet is a Sulfonamide antibiotic combination Small molecule drug developed by University of Oxford. It is currently in Phase 3 development for Bacterial infections (urinary tract infections, respiratory tract infections, otitis media), Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment, Toxoplasmosis. Also known as: Cosatrim, Septrin, Bactrim.

Cotrimoxazole is a fixed-dose combination of sulfamethoxazole and trimethoprim that inhibits bacterial folate synthesis at two sequential steps, preventing DNA replication.

Cotrimoxazole is a fixed-dose combination of sulfamethoxazole and trimethoprim that inhibits bacterial folate synthesis at two sequential steps, preventing DNA replication. Used for Bacterial infections (urinary tract infections, respiratory tract infections, otitis media), Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment, Toxoplasmosis.

At a glance

Generic nameCotrimoxazole dispersible tablet
Also known asCosatrim, Septrin, Bactrim
SponsorUniversity of Oxford
Drug classSulfonamide antibiotic combination
TargetDihydropteroate synthase and dihydrofolate reductase
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Sulfamethoxazole inhibits dihydropteroate synthase, while trimethoprim inhibits dihydrofolate reductase. Together, they block the bacterial synthesis of dihydrofolate and tetrahydrofolate, essential cofactors for nucleotide synthesis. This synergistic dual inhibition is bactericidal and provides broad-spectrum coverage against many gram-positive and gram-negative organisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cotrimoxazole dispersible tablet

What is Cotrimoxazole dispersible tablet?

Cotrimoxazole dispersible tablet is a Sulfonamide antibiotic combination drug developed by University of Oxford, indicated for Bacterial infections (urinary tract infections, respiratory tract infections, otitis media), Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment, Toxoplasmosis.

How does Cotrimoxazole dispersible tablet work?

Cotrimoxazole is a fixed-dose combination of sulfamethoxazole and trimethoprim that inhibits bacterial folate synthesis at two sequential steps, preventing DNA replication.

What is Cotrimoxazole dispersible tablet used for?

Cotrimoxazole dispersible tablet is indicated for Bacterial infections (urinary tract infections, respiratory tract infections, otitis media), Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment, Toxoplasmosis.

Who makes Cotrimoxazole dispersible tablet?

Cotrimoxazole dispersible tablet is developed by University of Oxford (see full University of Oxford pipeline at /company/university-of-oxford).

Is Cotrimoxazole dispersible tablet also known as anything else?

Cotrimoxazole dispersible tablet is also known as Cosatrim, Septrin, Bactrim.

What drug class is Cotrimoxazole dispersible tablet in?

Cotrimoxazole dispersible tablet belongs to the Sulfonamide antibiotic combination class. See all Sulfonamide antibiotic combination drugs at /class/sulfonamide-antibiotic-combination.

What development phase is Cotrimoxazole dispersible tablet in?

Cotrimoxazole dispersible tablet is in Phase 3.

What are the side effects of Cotrimoxazole dispersible tablet?

Common side effects of Cotrimoxazole dispersible tablet include Rash, Nausea, Vomiting, Diarrhea, Hyperkalemia, Stevens-Johnson syndrome.

What does Cotrimoxazole dispersible tablet target?

Cotrimoxazole dispersible tablet targets Dihydropteroate synthase and dihydrofolate reductase and is a Sulfonamide antibiotic combination.

Related